Characterization of suspicious prostate lesions at multiparametric MRI with dynamic 68 Ga-Gozetotide PET/CT
Dynamic <sup>68</sup> Ga Gozetotide PET/CT imaging may offer enhanced discrimination of MRI-visible prostate cancer lesions and assist in management decisions. Study registered with the FDA (IND 144,177) and clinicaltrials.gov (NCT04179968).
Authors
- Daniel Parrott (ORCID: https://orcid.org/0000-0001-5871-3431)
- Daniella F. Pinho (ORCID: https://orcid.org/0000-0002-5149-6814)
- Qing Yuan (ORCID: https://orcid.org/0000-0001-9851-0284)
- Xiankai Sun (ORCID: https://orcid.org/0000-0002-5140-6110)
- Neil M. Rofsky (ORCID: https://orcid.org/0000-0002-1207-3704)
- Iván Pedrosa (ORCID: https://orcid.org/0000-0002-0371-8689)
- Marianna Dakanali
- S Bowen (ORCID: https://orcid.org/0000-0001-6681-3424)
- Orhan K. Öz (ORCID: https://orcid.org/0000-0002-5846-6829)
- Alberto Diaz de Leon
- Yin Xi (ORCID: https://orcid.org/0000-0001-9743-3010)
- Daniel N. Costa (ORCID: https://orcid.org/0000-0002-2890-5720)
- Dana Mathews
Institutions
- Mount Sinai Health System (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Michigan (US)
- NYU Langone Health (US)
- Southwestern Medical Center (US)
- Radiology Associates (US)
- New York University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- EJNMMI Reports
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1186/s41824-025-00268-2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Texas Southwestern Medical Center